Results 131 to 140 of about 301,814 (290)

Detecting Population III Gamma-Ray Bursts with Einstein Probe and Space-based Multiband Astronomical Variable Objects Monitor

open access: yesThe Astrophysical Journal
High-redshift gamma-ray bursts (GRBs), putative counterparts of massive, low-metallicity population III (Pop III) stars, are a promising probe of the first stars.
Jun-Jie Wei, Qing-Bo Ma, Xue-Feng Wu
doaj   +1 more source

Potential therapeutic targeting of BKCa channels in glioblastoma treatment

open access: yesMolecular Oncology, EarlyView.
This review summarizes current insights into the role of BKCa and mitoBKCa channels in glioblastoma biology, their potential classification as oncochannels, and the emerging pharmacological strategies targeting these channels, emphasizing the translational challenges in developing BKCa‐directed therapies for glioblastoma treatment.
Kamila Maliszewska‐Olejniczak   +4 more
wiley   +1 more source

PARP inhibition and pharmacological ascorbate demonstrate synergy in castration‐resistant prostate cancer

open access: yesMolecular Oncology, EarlyView.
Pharmacologic ascorbate (vitamin C) increases ROS, disrupts cellular metabolism, and induces DNA damage in CRPC cells. These effects sensitize tumors to PARP inhibition, producing synergistic growth suppression with olaparib in vitro and significantly delayed tumor progression in vivo. Pyruvate rescue confirms ROS‐dependent activity.
Nicolas Gordon   +13 more
wiley   +1 more source

Where are the Population III Star Relics in the Simulated Milky Way Analogs?

open access: yesThe Astrophysical Journal
Using six Milky Way analogs with two different numerical resolutions from the Auriga simulation, we investigate the total mass, spatial distribution, and kinematics of the Population III (Pop III) star relics in the Milky Way analogs at z = 0.
Hang Yang   +5 more
doaj   +1 more source

Eruptive mass loss in very massive stars and Population III stars [PDF]

open access: yes, 2009
12 pages, 4 figs. To appear in proceedings of STScI May Symposium 2006, "Massive Stars: From Pop III and GRBs to the Milky Way".
openaire   +2 more sources

Plecstatin inhibits hepatocellular carcinoma tumorigenesis and invasion through cytolinker plectin

open access: yesMolecular Oncology, EarlyView.
The ruthenium‐based metallodrug plecstatin exerts its anticancer effect in hepatocellular carcinoma (HCC) primarily through selective targeting of plectin. By disrupting plectin‐mediated cytoskeletal organization, plecstatin inhibits anchorage‐dependent growth, cell polarization, and tumor cell dissemination.
Zuzana Outla   +10 more
wiley   +1 more source

On the Pair-instability Supernova Origin of J1010+2358

open access: yesThe Astrophysical Journal Letters
The first (Population III) stars formed only out of H and He and were likely more massive than present-day stars. Massive Population III stars in the range 140–260 M _⊙ are predicted to end their lives as pair-instability supernovae (PISNe), enriching ...
Ása Skúladóttir   +6 more
doaj   +1 more source

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

open access: yesMolecular Oncology, EarlyView.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon   +9 more
wiley   +1 more source

A Bayesian Exploration of The Mass of the Ursa Major III: Kinematics, Rotation and their influence on the Mass to Light Ratio

open access: yesThe Open Journal of Astrophysics
We investigate the kinematics of the potential ultra-faint dwarf galaxy (UFD) UMa III/U1 using Bayesian inference to search for the signal of any potential intrinsic rotation.
Tim R. Adams   +2 more
doaj   +1 more source

TRAIL‐PEG‐Apt‐PLGA nanosystem as an aptamer‐targeted drug delivery system potential for triple‐negative breast cancer therapy using in vivo mouse model

open access: yesMolecular Oncology, EarlyView.
Aptamers are used both therapeutically and as targeting agents in cancer treatment. We developed an aptamer‐targeted PLGA–TRAIL nanosystem that exhibited superior therapeutic efficacy in NOD/SCID breast cancer models. This nanosystem represents a novel biotechnological drug candidate for suppressing resistance development in breast cancer.
Gulen Melike Demirbolat   +8 more
wiley   +1 more source

Home - About - Disclaimer - Privacy